CYCLE-1
Open-label, Phase I, Multi-center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients the Recommended Dose of CYAD-02 After a Non-myeloablative Preconditioning Chemotherapy Followed by a Potential Consolidation Cycle
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 27 patients (estimated)
- Sponsors
- Celyad Therapeutics
- Tags
- CAR T Cell, Chemotherapy, NKG2D
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1588
- NCT Identifier
- NCT04167696
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.